A DOSE FINDING COMPARATIVE STUDY OF ME 1207 FOR COMPLICATED URINARY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 40; no. Supplement2; pp. 543 - 558
• Main Authors: Arakawa, Soich, Kamidono, Sadao, Matsumoto, Tetsuro, Tanaka, Masatoshi, Kumazawa, Joichi, Hirooka, Kuhei, Kataoka, Nobumasa, Ogawa, Nobuya
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1992
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.40.Supplement2_543

We performed a dose-finding study on ME 1207, a new oral cephem, in the treatment of complicated urinary tract infections (UTI) without indwelling catheter by comparing with cefteram pivoxil (CFTM-PI) as a control drug. Patients with infections caused by Pseudomonas sp. were excepted in the study. ME 1207 was orally administered at a daily dose of 300mg and 600mg, and CFTM-PI was also orally administered at a daily dose of 300mg, for 5 days. The clinical efficacy evaluated according to the criteria of the Japanese UTI Committee was 75.0%(36/48) in the ME 1207 300mg group, 76.6%(36/47) in the ME 1207 600mg group and 64.3%(27/42) in the CFTM-PI group, there were no significant differences among the three groups. As for the bacteriological response, the eradication rate was 71.2%(37/52) in the ME 1207 300mg group, 82.0%(41/50) in the ME 1207 600mg group and 75.5%(37/49) in the CFTM-PI group. There were no significant differences among the three groups. Theincidence of side effects was 6.1%(4/66) in the ME 1207 300mg group, 1.5%(1/68) in the ME 1207 600mg group and 1.4%(1/69) in the CFTM-PI group. There were no significant differences among the three groups. Regarding abnormal laboratory findings, there were no significant differences among the three groups. We concluded that 300mg per day was the optimal dose of ME 1207 for the treatment of complicated UTI.